Anixa Biosciences
Anixa Biosciences is a biotechnology company that researches, develops and commercializes novel therapeutics for the treatment of cancer.
Business Model:
Revenue: $1.8M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Anixa Biosciences Information
Geographic Data
Address: 3150 Almaden Expressway
City: San Jose
State: CA
Zip: 95118
Country: US
Financial Info
Stage:
grant
Raised Last:
$0
Raised Total:$8M
Social
Metrics
3,186,808Website Global Rank
4,435Website Monthly Traffic
Twitter Followers
Description
Anixa Biosciences is a biotechnology company that researches, develops and commercializes novel therapeutics for the treatment of cancer.
Contact Phone:
Contact Email:
Anixa Biosciences went public on 7/9/2015 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
7/9/2015
Ticker Symbol:
ANIX
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2013 | Debt | $1.8M | 4/2013 | Equity | $500k | 11/2013 | Post-IPO Equity | $3.5M | 8/2011 | Equity | $1.3M | 12/2012 | Debt | $750k | 5/2021 | Grant | 1 | - |
National Cancer Institute National Cancer Institute |
7/2014 | Post-IPO Equity | $4M | 9/2012 | Post-IPO Debt | $750k | 2/2013 | Post-IPO Debt | $1.8M | 3/2021 | Post-IPO Equity | $22.5M | 2/2011 | Post-IPO Equity | $1.3M | 5/2013 | Post-IPO Equity | $500k | 5/2021 | Grant | 1 | - |
National Cancer Institute National Cancer Institute |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
